Media releases 03 Oct 2016
Tamoxifen added to PBS for women at increased risk of breast cancer
BCNA welcomes the announcement by Federal Health Minister Sussan Ley that Nolvadex (tamoxifen) has been listed on the Pharmaceutical Benefits Scheme (PBS) for women at moderate or high risk of developing breast cancer.
Tamoxifen is a well known and very effective breast cancer treatment.
Recent large international clinical trials have found that tamoxifen is also a very effective treatment for women who have not had breast cancer but are at moderate or high risk of developing it. The trials found that taking tamoxifen every day for five years can reduce a woman’s risk of developing breast cancer by more than 30% over a 20 year period.
Women who want to reduce their risk of breast cancer will welcome the listing of Nolvadex on the PBS, as the only other option available is to undergo major surgery to remove both their breasts.
If you are at increased risk of developing breast cancer, you may like to talk to your doctor about whether Nolvadex is a suitable option for you.
The listing of Nolvadex for this purpose took effect on Saturday 1 October 2016.